CDC found 145 patients harmed after travelling for cosmetic surgery. Nobody knows the real number.

The agency reviewed a decade of its own consultations and called for stronger surveillance. Until that exists, the only protection a patient has is upstream: an independent answer to whether the procedure is warranted at all.

In June, the CDC published a review in Emerging Infectious Diseases of what happened to Americans who travelled for elective cosmetic procedures between 2014 and 2024. The findings are narrow in scope and uncomfortable in substance.

Researchers identified 21 reports involving roughly 145 patients with adverse outcomes. Post-surgical infections appeared in 20 consultations, 12 of them suspected or confirmed nontuberculous mycobacteria, an organism notoriously resistant to standard antibiotics. Four consultations involved patient deaths. Infection prevention assessments carried out during two of the investigations, one domestic and one international, found deficiencies in environmental cleaning, hand hygiene, protective equipment and the reprocessing of surgical instruments.

"More and more people are getting medical procedures outside the United States, but there are risks," said Kiara McNamara, the CDC nurse epidemiologist who led the study.

Two features of this study matter more than the casualty count, and both have been largely overlooked.

The denominator does not exist

These 34 travel-related cases were drawn from 2,162 consultations CDC handled over the period. They are not a measured incidence rate. They are the cases that surfaced, usually because a state health department noticed a cluster and called the agency.

Consider what has to happen for a patient to appear in this dataset. The complication must be serious enough to reach medical attention. A clinician must connect it to a procedure performed somewhere else, often weeks earlier and in another country. That clinician must report it. A health department must escalate it. CDC must be consulted.

A patient who develops a wound infection, sees a local doctor, receives antibiotics and recovers slowly never enters the count. Neither does one who is treated privately and says nothing. The CDC's own recommendation, issued alongside the findings, is for stronger surveillance systems and better collaboration between providers and public health agencies. That is an agency stating plainly that the current picture is incomplete.

So the honest position is this: millions of people cross borders for medical care every year, national governments are actively working to increase that number, and no one can say with confidence how often it goes wrong.

This is not a story about foreign hospitals

The second overlooked detail is that the CDC review covered patients who travelled both within and outside the United States. Domestic clinics appear in the findings alongside international ones. The 2023 Florida outbreak that CDC investigated, in which fifteen patients acquired Mycobacterium abscessus after procedures at a single south Florida clinic, involved no border crossing at all.

That undercuts the reflex reading of studies like this one, which is that care abroad is dangerous and care at home is safe. The variable that matters is not the passport stamp. It is whether anyone verified the facility, whether the procedure was appropriate in the first place, and whether anybody is accountable for the patient after the dressing comes off.

Those three things can be absent thirty minutes from home. They are simply harder to arrange across an ocean.

The market is scaling faster than its evidence base

Meanwhile, destination countries are accelerating. In September, India's Commerce and Industry Minister Piyush Goyal called for the country to serve 10 million medical value travellers a year, against roughly 3.5 million over the preceding seven years combined. Thailand, Turkey, the UAE, Malaysia, Mexico and South Korea are all competing for the same patients.

These are legitimate ambitions built on real clinical capability. But an industry expanding this quickly, with the outcome data CDC has just described as insufficient, is asking patients to make consequential decisions on information that does not exist.

Which raises a practical question. If a patient cannot compare outcomes, because nobody publishes them in a form that would allow it, what can she actually control?

The only lever left is the decision itself

She can control whether the procedure is necessary.

The conventional cross-border healthcare journey begins with a destination. A patient learns that a procedure is expensive, delayed or unavailable at home, and starts searching. Which country. Which hospital? Which surgeon? What does the package include? Within an afternoon she can have physician biographies, testimonials, price quotations and a facilitator ready to coordinate visas.

Every one of those questions is medical. None of them is answered by a treatment package. And unlike infection rates at a clinic 8,000 kilometres away, all of them are answerable before anyone books a flight.

The first product in cross-border healthcare should not be an itinerary. It should be a second opinion, delivered by a specialist who has no stake in the answer.

Nobody is paid to say no

That is harder to arrange than it sounds, because of how the industry earns money.

Hospitals are paid to treat. Facilitators are paid to place. Travel businesses are paid when people move. None of this is improper on its own. The structural problem is that the same commercial pathway that benefits when a patient travels is usually also the patient's main source of advice on whether travelling is necessary. Even where everyone behaves ethically, a patient has no way to tell the difference from the outside.

The fix is structural rather than moral. Separate the clinical review from the travel transaction, and pay the reviewing specialist the same fixed fee whichever conclusion the records support: proceed, test further, treat differently, or stay home.

Then publish how often the answer is "stay home."

Call it the don't-travel rate. The point is not to maximise it. A very high rate would be as suspect as a very low one. The point is that it is verifiable, repeatable and directly contrary to the publisher's commercial interest, which is precisely what makes it informative. An organisation that reports only how many patients it successfully sent abroad has told the patient nothing about its judgement.

At Healing Tourist, the second-opinion platform I founded, specialists advised against international travel in 31.4 percent of 412 completed case reviews, with the fee fixed regardless of outcome. That is one operator's case mix on a small base, and it should not be read as a benchmark. It is offered because a metric nobody reports is not a metric, and because the only way to learn whether 31 percent is high, low or unremarkable is for others to publish theirs.

Records have to make the return trip

The CDC's standing guidance to medical travellers is worth reading as a description of what the system currently fails to do. It advises patients to discuss plans with their regular clinician before going, to agree in advance with both home and overseas doctors how complications will be handled, to obtain copies of their overseas records in English, and not to delay care if something goes wrong after returning.

Every one of those is advice to the patient because no institution reliably does it for her. The surgeon who performed the operation may be unreachable when a wound turns. The doctor she sees at home may have no operative report. The implant may be unfamiliar. Her insurer may decline to cover the consequences of a procedure it did not authorise.

An episode of care that ends at the airport is not an episode of care. It is a transaction with medical content.

The most useful answer may be no

None of this is an argument against seeking treatment abroad. Patients find expertise overseas that does not exist near them, and prices that make impossible care possible. Expanded choice is a real gain.

But choice without evidence is not choice, and the CDC has now documented, in its own cautious institutional language, how thin the evidence is. Until that changes, the most valuable thing this industry can offer is not a better destination.

It is an honest, independent, disinterested answer to the question patients are currently asked last: does this person need to get on a plane at all?

Chida Khatua is the founder of Healing Tourist (healingtourist.com), a medical second-opinion and treatment-facilitation platform that pays panel specialists a fixed review fee irrespective of whether the patient is advised to travel, and publishes the share of cases in which travel is not recommended.